Inven2, established 15 years ago, is a key player in Norway's innovation ecosystem, focusing on commercializing research and innovation within life sciences and other research areas. They collaborate with researchers, entrepreneurs, investors, and other partners to transform research and knowledge into beneficial products and services. Inven2 actively contributes to clinical studies, working with hospitals and industry to ensure efficient study execution for the benefit of Norwegian patients. Their portfolio consists of approximately 40 companies, established either independently or with investors, based on research results from innovative researchers. The portfolio value as of December 2025 is 4 billion NOK. Inven2 has facilitated the introduction of numerous products and services to the market through licensing to industry or company establishment across various technology domains.
Preferred startup development maturity for initial funding deployment.
Commercialization of research-driven innovations, particularly in biotech, medical technologies, and clinical solutions
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...